1606 Corp. files Q3 10-Q, signs LOI with Adnexus Biotechnologies

1606 CORP.

Filed Q3 10-Q for period ended September 30, 2024, maintaining continuous quarterly filings since inception.
Signed Letter of Intent with Adnexus Biotechnologies for a potential strategic investment in AI and biotech.
No financial metrics reported; press release focuses on narrative progress and forward-looking outlook.
CEO plans to close Adnexus investment and expand AI chatbot solutions into healthcare, finance, and telecom.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.